The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Pheezee is designed to assess musculoskeletal and neuromuscular health.
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Subscribe To Our Newsletter & Stay Updated
